Agenus (NASDAQ:AGEN) Now Covered by Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Agenus (NASDAQ:AGEN) in a report published on Monday, Marketbeat reports. The brokerage issued a buy rating and a $19.00 price target on the biotechnology company’s stock.

Several other equities research analysts have also recently commented on the company. Chardan Capital started coverage on Agenus in a research report on Friday, September 18th. They set a “buy” rating and a $40.00 price objective on the stock. Wall Street Zen lowered Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. HC Wainwright restated a “buy” rating and set a $25.00 target price (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th. B. Riley Financial restated a “buy” rating and set a $14.00 target price (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Finally, Weiss Ratings downgraded shares of Agenus from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, August 21st. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.50.

Agenus Trading Up 10.4%

AGEN stock opened at $9.43 on Monday. The stock has a market capitalization of $425.86 million, a PE ratio of 3.66 and a beta of 1.38. Agenus has a 12-month low of $2.71 and a 12-month high of $9.71. The stock’s 50 day simple moving average is $7.49 and its 200 day simple moving average is $4.99.

Agenus (NASDAQ:AGEN) last posted its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). Agenus had a negative return on equity of 47.68% and a net margin of 69.33%.The business had revenue of $34.52 million during the quarter, compared to the consensus estimate of $34.00 million. On average, research analysts predict that Agenus will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

Hedge funds and other institutional investors have recently made changes to their positions in the business. Redwood Family Wealth LLC bought a new position in shares of Agenus in the 4th quarter worth approximately $44,000. Ovata Capital Management Ltd bought a new stake in Agenus during the fourth quarter valued at approximately $97,000. Bank of New York Mellon Corp bought a new stake in Agenus during the second quarter valued at approximately $311,000. Bank of America Corp DE increased its holdings in Agenus by 796.7% during the first quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock valued at $397,000 after buying an additional 105,536 shares during the last quarter. Finally, Globeflex Capital L P purchased a new stake in Agenus during the second quarter valued at approximately $1,281,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. Its research programs are designed to activate and direct the immune system against tumors, with an emphasis on therapies that may address immune resistance and improve responses in difficult-to-treat cancers.

The company’s pipeline has included checkpoint inhibitors, cancer vaccines, immune-stimulating adjuvants, bispecific antibodies and other antibody-based therapies.